3,883
edits
Changes
Breast Cancer Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray (view source)
Revision as of 17:42, 22 April 2021
, 17:42, 22 April 2021no edit summary
'''Table 1 - Clinically significant copy number alterations in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
'''Table 1 - Clinically significant copy number alterations and regions of loss of heterozygosity in breast cancer.''' Table derived from Geiersbach et al., 2018 [[https://pubmed.ncbi.nlm.nih.gov/32087595/ PMID 32087595]] with permission from Cancer Genetics.<ref>{{Cite journal|last=Geiersbach|first=Katherine B.|last2=Chen|first2=Hui|last3=Emmadi|first3=Rajyasree|last4=Haskell|first4=Gloria T.|last5=Lu|first5=Xinyan|last6=Liu|first6=Yajuan J.|last7=Swisshelm|first7=Karen|date=2020-06|title=Current concepts in breast cancer genomics: An evidence based review by the CGC breast cancer working group|url=https://pubmed.ncbi.nlm.nih.gov/32087595|journal=Cancer Genetics|volume=244|pages=11–20|doi=10.1016/j.cancergen.2020.02.002|issn=2210-7762|pmid=32087595}}</ref>
{| class="wikitable"
{| class="wikitable"
|'''Alteration'''
|'''Alteration'''
|'''Relevant Gene(s)'''
|'''Relevant Gene(s)'''
|'''CGC Evidence Level'''
|'''CGC Evidence Level'''†
|'''Subgroup Association(s)'''
|'''Subgroup Association(s)'''
|-
|-
|METABRIC IntClust1, ER Positive
|METABRIC IntClust1, ER Positive
|}
|}
Abbreviations: TNBC, triple negative breast cancer.
† See table below Table 2 for CGC Evidence levels
Abbreviations: TNBC, triple negative breast cancer; LOH, loss of heterozygosity.
'''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
'''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer.''' Table derived from Geiersbach et al., 2018 [[https://pubmed.ncbi.nlm.nih.gov/32087595/ PMID 32087595]] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Gene(s)'''
|'''Gene(s)'''
|'''CGC Evidence Level'''
|'''CGC Evidence Level'''†
|'''Clinical Significance and Subgroup Association(s)'''
|'''Clinical Significance and Subgroup Association(s)'''
|'''Therapy Implication(s)'''
|'''Therapy Implication(s)'''
|PARP inhibitors (germline)
|PARP inhibitors (germline)
|-
|-
|''[[BRCA1 syndrome|BRCA1]], [[BRCA2 syndrome|BRCA2]]''
|''[[BRCA1]], [[BRCA2]]''
|1
|1
|Often hereditary risk; TNBC
|Often hereditary risk; TNBC
Abbreviations: BC, breast cancer. TNBC, triple negative breast cancer.
Abbreviations: BC, breast cancer. TNBC, triple negative breast cancer.
'''Cancer Genomics Consortium Levels of Evidence'''
†'''Cancer Genomics Consortium Levels of Evidence'''
{| class="wikitable"
{| class="wikitable"
|'''Tier'''
|'''Tier'''
|Benign or likely benign
|Benign or likely benign
|}
|}
'''Table 3 - Genes with known hereditary risk associations in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics.
'''Table 3 - Genes with known hereditary risk associations in breast cancer.''' Table derived from Geiersbach et al., 2018 [[https://pubmed.ncbi.nlm.nih.gov/32087595/ PMID 32087595]] with permission from Cancer Genetics.
{| class="wikitable"
{| class="wikitable"
|'''Gene'''
|'''Gene'''
|TNBC
|TNBC
|-
|-
|''BRCA1''
|''[[BRCA1]]''
|[[BRCA1 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC
|[[BRCA1 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC
|-
|-
|''BRCA2''
|''[[BRCA2]]''
|[[BRCA2 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC
|[[BRCA2 syndrome|BRCA-Related Breast/ Ovarian Cancer Syndrome]]; TNBC
|-
|-
|}
|}
Abbreviations: TNBC, triple negative breast cancer.
Abbreviations: TNBC, triple negative breast cancer.
==Reference==
<references />